Most Read Articles
Audrey Abella, 2 months ago
Fixed-dose combinations of long-acting β2-agonist (LABA) and muscarinic antagonist (LAMA) offered superior efficacy and comparable safety to LAMA or LABA/inhaled corticosteroid (ICS), the two most commonly prescribed first-line treatments for stable moderate-to-very-severe chronic obstructive pulmonary disease (COPD), according to a meta-analysis.
one year ago
At a recent continuing medical education programme, Dr Neil G Snowise, Regional Medical Leader of GlaxoSmithKline Global Respiratory Franchise shed light on the clinical efficacy of Relvar® Ellipta® (fluticasone furoate/vilanterol) for the management of asthma. Highlights of his presentation are summarized below.
one year ago
Afatinib is a potential treatment for metastatic squamous cell carcinoma, a review states.
one year ago
Diabetes mellitus patients have higher risk of developing tuberculosis, especially during the first 12 months following diagnosis, according to a retrospective cohort study.

New Product Highlight - Flutiform

2 years ago
FLUTIFORM®– Fluticasone propionate and Formoterol fumarate Inhalation 50 mcg/5 mcg, 125 mcg/5 mcg and 250 mcg/10 mcg  
• flutiform® combines the ICS and LABA that doctors prefer:1,2
     - Well-tolerated and potent anti-inflammatory effects of fluticasone1-5
     - Fast onset and sustained bronchodilatory action of formoterol1-5
• flutiform® delivers a consistently high fine particle fraction across flow rates.6

References:
1. Price D, Bousquet J. Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma. Resp Med 2012; 106 (S1): S4-S8.
2.
Thomas M, Haughney J, Price D. Physicians’ attitudes towards combination therapy with inhaled corticosteroids and long-acting β2-agonist: an observational study in UK specialist care. Prag Obs Res 2011; 2: 25-31.
3. Flutiform® Approved Prescribing Information/Data Sheet.
4. Bodzenta-Lukaszyk A et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatmentof asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011; 11: 28-37.
5. Aalbers R et al. Onset ofbronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther 2012; 29 (11):958-969.
6.
Johal B, Howald M, Fischer M, Marshall J. Comparison of the fine particle fraction of fluticasone propionate/formoterol fumarate combination with other combination products. Poster presented at the European Respiratory Society (ERS) 22nd Annual Congress, 1–5 September 2012, Vienna,Austria.

Further information available in Section 3b, New in This Issue and mims.com.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 2 months ago
Fixed-dose combinations of long-acting β2-agonist (LABA) and muscarinic antagonist (LAMA) offered superior efficacy and comparable safety to LAMA or LABA/inhaled corticosteroid (ICS), the two most commonly prescribed first-line treatments for stable moderate-to-very-severe chronic obstructive pulmonary disease (COPD), according to a meta-analysis.
one year ago
At a recent continuing medical education programme, Dr Neil G Snowise, Regional Medical Leader of GlaxoSmithKline Global Respiratory Franchise shed light on the clinical efficacy of Relvar® Ellipta® (fluticasone furoate/vilanterol) for the management of asthma. Highlights of his presentation are summarized below.
one year ago
Afatinib is a potential treatment for metastatic squamous cell carcinoma, a review states.
one year ago
Diabetes mellitus patients have higher risk of developing tuberculosis, especially during the first 12 months following diagnosis, according to a retrospective cohort study.